Second Malignancies After Radiation Treatment and Chemotherapy for Primary Cancers

  • Lydia B. Zablotska
  • Matthew J. Matasar
  • Alfred I. Neugut


Cancer survivors have been shown to have an increased risk for second malignant neoplasms (SMN). These increased risks result from genetic predisposition, harmful environmental exposures, or cancer treatment therapies. Regardless of their cause, SMNs now comprise the sixth most common group of malignancies after skin, prostate, breast, lung, and colorectal cancers.1 It is important to emphasize that the fear of SMN related to the treatment of the first cancer diagnosis should not outweigh the positive effects of curative therapy for the first cancer. Both physicians and patients should, however, be aware of the consequences of the cancer treatment regimens, specifically radiation therapy (RT) and chemotherapy, and consider them while devising follow-up plans.


Breast Cancer Clin Oncol Radiat Oncol Biol Phys Childhood Cancer Natl Cancer Inst 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Neugut AI, Meadows AT, Robinson E (eds). Multiple primary cancers. Philadelphia: Lippincott Williams & Wilkins, 1999.Google Scholar
  2. 2.
    Goolden WG. Radiation cancer of the pharynx. Br Med J 1951;2:1110–1117.PubMedGoogle Scholar
  3. 3.
    Sherrill DJ, Grishkin BA, Galal FS, Zajtchuk R, Graeber GM. Radiation associated malignancies of the esophagus. Cancer (Phila) 1984;54(4):726–728.PubMedGoogle Scholar
  4. 4.
    Shimizu T, Matsui T, Kimura O, Maeta M, Koga S. Radiation-induced esophageal cancer: a case report and a review of the literature. Jpn J Surg 1990;20(1):97–100.PubMedGoogle Scholar
  5. 5.
    Ribeiro U Jr, Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg 1996;83(9):1174–1185.PubMedGoogle Scholar
  6. 6.
    Neugut AI, Weinberg MD, Ahsan H, Rescigno J. Carcinogenic effects of radiotherapy for breast cancer. Oncology (Huntingt) 1999;13(9):1245–1256; discussion 57, 61–65.PubMedGoogle Scholar
  7. 7.
    Boice JD Jr. Studies of atomic bomb survivors. Understanding radiation effects. JAMA 1990;264(5):622–623.PubMedGoogle Scholar
  8. 8.
    Pierce DA, Preston DL. Radiation-related cancer risks at low doses among atomic bomb survivors. Radiat Res 2000;154(2):178–186.PubMedGoogle Scholar
  9. 9.
    UNSCEAR (United Nations Scientific Committee on the Effects of Atomic Radiation). 2000 Report to the General Assembly, with Scientific Annexes. Volume II: Effects. New York: United Nations, 2000.Google Scholar
  10. 10.
    Tucker MA, Meadows AT, Boice JD Jr, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987;78(3):459–464.PubMedGoogle Scholar
  11. 11.
    Hawkins MM, Wilson LM, Stovall MA, et al. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. BMJ 1992;304(6832):951–958.PubMedGoogle Scholar
  12. 12.
    Tucker MA, D’Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987;317(10):588–593.PubMedGoogle Scholar
  13. 13.
    de Vathaire F, Francois P, Hill C, et al. Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 1989;59(5):792–796.PubMedGoogle Scholar
  14. 14.
    Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325(19):1330–1336.PubMedGoogle Scholar
  15. 15.
    Tucker MA, Jones PH, Boice JD Jr, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 1991;51(11):2885–2888.PubMedGoogle Scholar
  16. 16.
    Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141(3):259–277.PubMedGoogle Scholar
  17. 17.
    Olsen JH, Garwicz S, Hertz H, et al. Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ 1993;307(6911):1030–1036.PubMedGoogle Scholar
  18. 18.
    Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93(8):618–629.PubMedGoogle Scholar
  19. 19.
    Boice JD Jr. Radiation and non-Hodgkin’s lymphoma. Cancer Res 1992;52(19 suppl):5489s–5491s.PubMedGoogle Scholar
  20. 20.
    Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997;336(13):897–904.PubMedGoogle Scholar
  21. 21.
    Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000;18(2):348–357.PubMedGoogle Scholar
  22. 22.
    Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin’s disease. Cancer Treat Rev 2000;26(4):291–302.PubMedGoogle Scholar
  23. 23.
    Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996;334(12):745–751.PubMedGoogle Scholar
  24. 24.
    Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002;94(3):182–192.PubMedGoogle Scholar
  25. 25.
    Birdwell SH, Hancock SL, Varghese A, Cox RS, Hoppe RT. Gastrointestinal cancer after treatment of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1997;37(1):67–73.PubMedGoogle Scholar
  26. 26.
    Ron E, Preston DL, Mabuchi K, Thompson DE, Soda M. Cancer incidence in atomic bomb survivors. Part IV: Comparison of cancer incidence and mortality. Radiat Res 1994;137(2 suppl):S98–S112.PubMedGoogle Scholar
  27. 27.
    Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18(3):498–509.PubMedGoogle Scholar
  28. 28.
    Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol 2000;18(12):2435–2443.PubMedGoogle Scholar
  29. 29.
    Curtis RE, Boice JD Jr, Stovall M, Flannery JT, Moloney WC. Leukemia risk following radiotherapy for breast cancer. J Clin Oncol 1989;7(1):21–29.PubMedGoogle Scholar
  30. 30.
    Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326(26):1745–1751.PubMedGoogle Scholar
  31. 31.
    Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992;326(12):781–785.PubMedGoogle Scholar
  32. 32.
    Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1994;86(13):983–988.PubMedGoogle Scholar
  33. 33.
    Neugut AI, Murray T, Santos J, et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer (Phila) 1994;73(6):1615–1620.PubMedGoogle Scholar
  34. 34.
    Travis LB, Curtis RE, Inskip PD, Hankey BF. Re: Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1995;87(1):60–61.PubMedGoogle Scholar
  35. 35.
    Zablotska LB, Neugut AI. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer (Phila) 2003;97(6):1404–1411.PubMedGoogle Scholar
  36. 36.
    Rubino C, de Vathaire F, Diallo I, Shamsaldin A, Le MG. Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 2000;61(3):183–195.PubMedGoogle Scholar
  37. 37.
    Ahsan H, Neugut AI. Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Intern Med 1998;128(2):114–117.PubMedGoogle Scholar
  38. 38.
    Curtis RE, Boice JD Jr, Stovall M, et al. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 1994;86(17):1315–1324.PubMedGoogle Scholar
  39. 39.
    BEIR V (Committee on the Biological Effects of Ionizing Radiations). Health effects of exposure to low levels of ionizing radiation. Washington, DC: National Academy Press, 1990.Google Scholar
  40. 40.
    Bergfeldt K, Einhorn S, Rosendahl I, Hall P. Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish record-linkage study. Acta Oncol 1995;34(6):771–777.PubMedGoogle Scholar
  41. 41.
    Travis LB, Curtis RE, Boice JD Jr, Platz CE, Hankey BF, Fraumeni JF Jr. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 1996;56(7):1564–1570.PubMedGoogle Scholar
  42. 42.
    Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340(5):351–357.PubMedGoogle Scholar
  43. 43.
    Kaldor JM, Day NE, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990;322(1):1–6.PubMedGoogle Scholar
  44. 44.
    Kaldor JM, Day NE, Kittelmann B, et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int J Cancer 1995;63(1):1–6.PubMedGoogle Scholar
  45. 45.
    van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 1993;11(3):415–424.PubMedGoogle Scholar
  46. 46.
    Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92(14):1165–1171.PubMedGoogle Scholar
  47. 47.
    Boice JD Jr, Blettner M, Kleinerman RA, et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 1987;79(6):1295–1311.PubMedGoogle Scholar
  48. 48.
    Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin’s disease. N Engl J Med 1990;322(1):7–13.PubMedGoogle Scholar
  49. 49.
    Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res 1994;137(2 suppl):S68–S97.PubMedGoogle Scholar
  50. 50.
    Pawlish KS, Schottenfeld D, Severson R, Montie JE. Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study. Prostate 1997;33(2):75–86.PubMedGoogle Scholar
  51. 51.
    Movsas B, Hanlon AL, Pinover W, Hanks GE. Is there an increased risk of second primaries following prostate irradiation? Int J Radiat Oncol Biol Phys 1998;41(2):251–255.PubMedGoogle Scholar
  52. 52.
    Johnstone PA, Powell CR, Riffenburgh R, Rohde DC, Kane CJ. Second primary malignancies in T1-3N0 prostate cancer patients treated with radiation therapy with 10-year followup. J Urol 1998;159(3):946–949.PubMedGoogle Scholar
  53. 53.
    Neugut AI, Ahsan H, Robinson E, Ennis RD. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer (Phila) 1997;79(8):1600–1604.PubMedGoogle Scholar
  54. 54.
    Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997;89(23):1782–1878.PubMedGoogle Scholar
  55. 55.
    Salminen E, Pukkala E, Teppo L, Pyrhonen S. Risk of second cancers among lung cancer patients. Acta Oncol 1995;34(2):165–169.PubMedGoogle Scholar
  56. 56.
    Hoar SK, Wilson J, Blot WJ, McLaughlin JK, Winn DM, Kantor AF. Second cancer following cancer of the digestive system in Connecticut, 1935–82. Natl Cancer Inst Monogr 1985;68:49–82.PubMedGoogle Scholar
  57. 57.
    Knudson AG. Karnofsky Memorial Lecture. Hereditary cancer: theme and variations. J Clin Oncol 1997;15(10):3280–3287.PubMedGoogle Scholar
  58. 58.
    Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325(24):1682–1687.PubMedGoogle Scholar
  59. 59.
    Kimball Dalton VM, Gelber RD, Li F, Donnelly MJ, Tarbell NJ, Sallan SE. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16(8):2848–2853.PubMedGoogle Scholar
  60. 60.
    Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000;95(9):2770–2775.PubMedGoogle Scholar
  61. 61.
    Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998;12(3):346–352.PubMedGoogle Scholar
  62. 62.
    Meadows AT, Baum E, Fossati-Bellani F, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol 1985;3(4):532–538.PubMedGoogle Scholar
  63. 63.
    Kuttesch JF Jr, Wexler LH, Marcus RB, et al. Second malignancies after Ewing’s sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996;14(10):2818–2825.PubMedGoogle Scholar
  64. 64.
    Dunst J, Ahrens S, Paulussen M, et al. Second malignancies after treatment for Ewing’s sarcoma: a report of the CESS-studies. Int J Radiat Oncol Biol Phys 1998;42(2):379–384.PubMedGoogle Scholar
  65. 65.
    Rich DC, Corpron CA, Smith MB, Black CT, Lally KP, Andrassy RJ. Second malignant neoplasms in children after treatment of soft tissue sarcoma. J Pediatr Surg 1997;32(2):369–372.PubMedGoogle Scholar
  66. 66.
    Raney RB, Asmar L, Vassilopoulou-Sellin R, et al. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and-III. IRS Group of the Children’s Cancer Group and the Pediatric Oncology Group. Med Pediatr Oncol 1999;33(4):362–371.PubMedGoogle Scholar
  67. 67.
    Heyn R, Haeberlen V, Newton WA, et al. Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J Clin Oncol 1993;11(2):262–270.PubMedGoogle Scholar
  68. 68.
    Breslow NE, Takashima JR, Whitton JA, Moksness J, D’Angio GJ, Green DM. Second malignant neoplasms following treatment for Wilm’s tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 1995;13(8):1851–1859.PubMedGoogle Scholar
  69. 69.
    Green DM, Hyland A, Barcos MP, et al. Second malignant neoplasms after treatment for Hodgkin’s disease in childhood or adolescence. J Clin Oncol 2000;18(7):1492–1499.PubMedGoogle Scholar
  70. 70.
    van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000;18(3):487–497.PubMedGoogle Scholar
  71. 71.
    Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin’s disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001;19(6):1610–1618.PubMedGoogle Scholar
  72. 72.
    Boice JD Jr, Storm H, Curtis RE. Multiple primary cancers in Connecticut and Denmark. Monogr Natl Cancer Inst 1985;68(1):1–437.Google Scholar
  73. 73.
    Schatzkin A, Baranovsky A, Kessler LG. Diet and cancer. Evidence from associations of multiple primary cancers in the SEER program. Cancer (Phila) 1988;62(7):1451–1457.PubMedGoogle Scholar
  74. 74.
    Bergfeldt K, Nilsson B, Einhorn S, Hall P. Breast cancer risk in women with a primary ovarian cancer: a case-control study. Eur J Cancer 2001;37(17):2229–2234.PubMedGoogle Scholar
  75. 75.
    Inskip PD, Boice JD Jr. Radiotherapy-induced lung cancer among women who smoke. Cancer (Phila) 1994;73(6):1541–1543.PubMedGoogle Scholar
  76. 76.
    Saso R, Kulkarni S, Mitchell P, et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 2000;83(1):91–94.PubMedGoogle Scholar
  77. 77.
    Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995;87(18):1359–1364.PubMedGoogle Scholar
  78. 78.
    Curtis RE, Boice JD Jr, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996;88(12):832–834.PubMedGoogle Scholar
  79. 79.
    Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 2001;93(13):1008–1013.PubMedGoogle Scholar
  80. 80.
    Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356(9245):1876–1881.PubMedGoogle Scholar
  81. 81.
    King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286(18):2251–2256.PubMedGoogle Scholar
  82. 82.
    Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87(9):645–651.PubMedGoogle Scholar
  83. 83.
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86(7):527–537.PubMedGoogle Scholar
  84. 84.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371–1388.PubMedGoogle Scholar
  85. 85.
    Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353(9169):1993–2000.PubMedGoogle Scholar
  86. 86.
    Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344(26):1997–2008.PubMedGoogle Scholar
  87. 87.
    Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998;16(10):3386–3391.PubMedGoogle Scholar
  88. 88.
    Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 1999;83(6):860–863.PubMedGoogle Scholar
  89. 89.
    Ruther U, Dieckmann K, Bussar-Maatz R, Eisenberger F. Second malignancies following pure seminoma. Oncology 2000;58(1):75–82.PubMedGoogle Scholar
  90. 90.
    Hale GA, Marina NM, Jones-Wallace D, et al. Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol 1999;21(2):115–122.PubMedGoogle Scholar
  91. 91.
    Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89(19):1429–1439.PubMedGoogle Scholar
  92. 92.
    Hartmann JT, Nichols CR, Droz JP, et al. The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer (Phila) 2000;88(11):2629–2635.PubMedGoogle Scholar
  93. 93.
    Warren S, Gates DC. Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer 1932;16:1358–1414.Google Scholar
  94. 94.
    Lippman SM, Lee JJ, Karp DD. Phase III intergroup trial of 13-cis-retinoic acid to prevent second primary tumors in stage I non-small cell lung cancer (SNCLC): interim report of NCI No. I19-0001. Proc Am Soc Clin Oncol 1998;17:1753.Google Scholar
  95. 95.
    Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328(3):184–194.PubMedGoogle Scholar
  96. 96.
    Tepperman BS, Fitzpatrick PJ. Second respiratory and upper digestive tract cancers after oral cancer. Lancet 1981;2(8246):547–549.PubMedGoogle Scholar
  97. 97.
    Johnson BE, Bridges JD, Sobczeck M, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996;14(3):806–813.PubMedGoogle Scholar
  98. 98.
    Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study. Cancer (Phila) 1998;82(5):836–841.PubMedGoogle Scholar
  99. 99.
    Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340(4):265–271.PubMedGoogle Scholar
  100. 100.
    Heyne KH, Lippman SM, Lee JJ, Lee JS, Hong WK. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol 1992;10(10):1519–1524.PubMedGoogle Scholar
  101. 101.
    Thellenberg C, Malmer B, Tavelin B, Gronberg H. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol 2003;169(4):1345–1348.PubMedGoogle Scholar
  102. 102.
    Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 1986;105(3):360–367.PubMedGoogle Scholar
  103. 103.
    Kaldor JM, Day NE, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990;322(1):1–6.PubMedGoogle Scholar
  104. 104.
    Haas JF, Kittelmann B, Mehnert WH, et al. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer 1987;55(2):213–218.PubMedGoogle Scholar
  105. 105.
    Greene MH, Boice JD Jr, Greer BE, Blessing JA, Dembo AJ. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med 1982;307(23):1416–1421.PubMedGoogle Scholar
  106. 106.
    Ciancio G, Siquijor AP, Burke GW, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant 1997;11(3):243–249.PubMedGoogle Scholar
  107. 107.
    Andreone P, Gramenzi A, Lorenzini S, et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003;163(17):1997–2004.PubMedGoogle Scholar
  108. 108.
    Gross TG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999;23(3):251–258.PubMedGoogle Scholar
  109. 109.
    Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998;91(6):1833–1844.PubMedGoogle Scholar
  110. 110.
    Socie G, Kolb HJ. Malignant diseases after bone marrow transplantation: the case for tumor banking and continued reporting to registries. EBMT Late-Effects Working Party. Bone Marrow Transplant 1995;16(4):493–495.PubMedGoogle Scholar
  111. 111.
    Catena F, Nardo B, Liviano d’Arcangelo G, et al. De novo malignancies after organ transplantation. Transplant Proc 2001;33(1–2):1858–1859.PubMedGoogle Scholar
  112. 112.
    Valero JM, Rubio E, Moreno JM, Pons F, Sanchez-Turrion V, Cuervas-Mons V. De novo malignancies in liver transplantation. Transplant Proc 2003;35(2):709–711.PubMedGoogle Scholar
  113. 113.
    Dreno B. Skin cancers after transplantation. Nephrol Dial Transplant 2003;18(6):1052–1058.PubMedGoogle Scholar
  114. 114.
    Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 1993;85(1):25–31.PubMedGoogle Scholar
  115. 115.
    Tinger A, Wasserman TH, Klein EE, et al. The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique. Int J Radiat Oncol Biol Phys 1997;37(4):865–870.PubMedGoogle Scholar
  116. 116.
    Hudson MM, Poquette CA, Lee J, et al. Increased mortality after successful treatment for Hodgkin’s disease. J Clin Oncol 1998;16(11):3592–3600.PubMedGoogle Scholar
  117. 117.
    Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS. Second cancers following pediatric Hodgkin’s disease. J Clin Oncol 1998;16(2):536–544.PubMedGoogle Scholar
  118. 118.
    Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20(16):3484–3494.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Lydia B. Zablotska
    • 1
  • Matthew J. Matasar
    • 2
  • Alfred I. Neugut
    • 3
    • 4
  1. 1.Department of Epidemiology, Mailman School of Public HealthColumbia UniversityNew YorkUSA
  2. 2.Department of MedicineColumbia University Medical CenterNew YorkUSA
  3. 3.Department of EpidemiologyMailman School of Public HealthUSA
  4. 4.Department of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians and SurgeonsColumbia University Medical CenterNew YorkUSA

Personalised recommendations